» Authors » David J Browning

David J Browning

Explore the profile of David J Browning including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 94
Citations 2252
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shanmugam S, Browning D
Clin Ophthalmol . 2024 Nov; 18:3239-3247. PMID: 39555212
Purpose: Compare large language models (LLMs) in analyzing and responding to a difficult series of ophthalmic cases. Design: A comparative case series involving LLMs that met inclusion criteria tested on...
2.
Groothoff J, Browning D
Am J Ophthalmol . 2024 Oct; 270():245-251. PMID: 39369930
Purpose: To discuss the history and current state of private equity in ophthalmology, and to explore potential implications for ophthalmology practices, physicians, and patients. Design: Perspective. Methods: Selected articles in...
3.
Browning D
Clin Ophthalmol . 2024 Sep; 18:2539-2544. PMID: 39257592
Purpose: To highlight gaps in the professional ethics of ophthalmology. Design: Perspective. Methods: Presentation of problematic cases in ophthalmologic ethics with juxtaposition of ethical, legal, and conscientious viewpoints informed by...
4.
Browning D, Ong S, Clarkson J, Huang H
Am J Ophthalmol . 2024 Feb; 262:19-24. PMID: 38341168
Purpose: To review changes in the provision of charity eye care in the past 50 years with hypothesized resulting effects on surgical training and patient outcomes. Design: Perspective. Methods: Case...
5.
Rush R, Rush S, Reinauer R, Gomez Bastar P, Browning D
Retina . 2022 Mar; 42(7):1292-1301. PMID: 35263314
Purpose: To report updated clinical outcomes in subjects undergoing pars plana vitrectomy (PPV) using modern techniques and equipment for the treatment of proliferative diabetic retinopathy-related complications. Pooled analysis of five...
6.
Poor S, Weissgerber G, Adams C, Bhatt H, Browning D, Chastain J, et al.
Am J Ophthalmol . 2022 Mar; 239:180-189. PMID: 35247334
Purpose: To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti-vascular endothelial growth factor therapy over a 12-week period in...
7.
Ozawa H, Ueno S, Ohno-Tanaka A, Sakai T, Hashiguchi M, Shimizu M, et al.
Jpn J Ophthalmol . 2021 May; 65(4):472-481. PMID: 34014447
Purpose: To describe the characteristics of Japanese patients with hydroxychloroquine (HCQ) retinopathy developing within 3 years of treatment outset. Study Design: Retrospective case series METHODS: Three patients with HCQ retinopathy...
8.
Browning D, Greenberg P
Clin Ophthalmol . 2021 Apr; 15:1403-1408. PMID: 33854294
Purpose: To quantify the economic incentives associated with the choice of anti-VEGF drugs for retinal diseases. Methods: An economic model was created based on the distribution of use and number...
9.
Browning D, Yokogawa N, Greenberg P, Perlman E
Am J Ophthalmol . 2020 Nov; 222:400-401. PMID: 33228963
No abstract available.
10.
Rosenfeld P, Browning D
Am J Ophthalmol . 2020 Nov; 223:446-447. PMID: 33187630
No abstract available.